The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study

CNS Drugs
Esther GarciaYoshikatsu Terazawa


Blonanserin is a novel atypical antipsychotic agent with potent dopamine D(2) and serotonin 5-HT(2) antagonist properties. It may potentially have a lower incidence of adverse events than other antipsychotic agents. To determine the efficacy and safety of three doses of blonanserin compared with placebo and haloperidol in patients with acute-phase schizophrenia. This was a 6-week, randomized, double-blind, placebo- and haloperidol-controlled, international, multicentre study. Patients with an acute exacerbation of their schizophrenia, with a Positive and Negative Syndrome Scale (PANSS) score >/=70 and a Clinical Global Impression - Severity of Illness (CGI-S) score >/=4 ('moderately ill') [with no decrease >/=20% or >/=1 point, respectively, during the wash-out period] were randomized into one of five treatment groups (blonanserin 2.5, 5 or 10 mg, haloperidol 10 mg or placebo once daily). Patients were assessed weekly for clinical efficacy, adverse events, extrapyramidal symptoms (EPS) and drug compliance, and were assessed biweekly for other safety variables. All 307 randomized patients received at least one dose of study medication and 228 (74.3%) completed the study. The mean reduction in PANSS total score at week 6 was sign...Continue Reading


May 22, 2010·European Journal of Clinical Pharmacology·Junji SaruwatariSunao Kaneko
Apr 3, 2013·European Journal of Clinical Pharmacology·Melvin GeorgeSteven Aibor Dkhar
Aug 28, 2012·The Journal of Nervous and Mental Disease·Neil Krishan AggarwalRobert A Rosenheck
May 19, 2011·Clinical Neuropharmacology·Francisco López-Muñoz, Cecilio Álamo
Feb 3, 2011·Current Opinion in Psychiatry·Bruce J KinonSusan B Watson
Apr 27, 2010·Annals of General Psychiatry·Tsutomu Furuse, Kenji Hashimoto
May 13, 2010·Critical Care : the Official Journal of the Critical Care Forum·Benjamin SztrymfDidier Dreyfuss
Oct 19, 2010·Analytical Sciences : the International Journal of the Japan Society for Analytical Chemistry·Tadashi OgawaHiroshi Seno
Jun 15, 2013·Neuropsychiatric Disease and Treatment·Tomomi TenjinNoboru Yamaguchi
Dec 25, 2009·CNS Drugs·Emma D Deeks, Gillian M Keating
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Jun 4, 2014·Indian Journal of Psychiatry·T S Sathyanarayana Rao, Chittaranjan Andrade
Dec 1, 2012·Acta Neuropsychiatrica·Manabu TakakiYosuke Uchitomi
Dec 21, 2013·Expert Opinion on Pharmacotherapy·Naren P Rao, Gary Remington
May 14, 2011·Expert Opinion on Emerging Drugs·Falko Biedermann, W Wolfgang Fleischhacker
Jul 24, 2012·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Yu-Guan WenDe-Wei Shang
May 13, 2010·Pharmacology, Biochemistry, and Behavior·Yukihiro OhnoSaki Shimizu
Sep 13, 2015·Pharmacology, Biochemistry, and Behavior·Ayaka TataraYukihiro Ohno
May 20, 2014·Psychiatry and Clinical Neurosciences·Yuriko NinomiyaNoboru Yamaguchi
Jun 14, 2012·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tomoko InoueNoboru Yamaguchi
Aug 15, 2014·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Hirotake HidaYukihiro Noda
Dec 17, 2014·Journal of Clinical Psychopharmacology·Yutaka Mizuki, Manabu Takaki
Jun 28, 2016·Pharmacology & Therapeutics·Gian Marco LeggioFilippo Drago
Nov 19, 2013·The Cochrane Database of Systematic Reviews·Clive E AdamsStephen Lawrie
Nov 27, 2014·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Taro KishiNakao Iwata
Jul 30, 2019·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Young Sup WooWon-Myong Bahk
Sep 8, 2017·Critical Care : the Official Journal of the Critical Care Forum·Stéphane GaudryDidier Dreyfuss
Jun 22, 2018·Annals of General Psychiatry·Eun Hyun SeoHyung-Jun Yoon


May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1989·Paediatric and Perinatal Epidemiology·T BjerkedalD W Hosmer
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Jan 4, 1996·The New England Journal of Medicine·John M Kane
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·H Y MeltzerJunji Ichikawa
Mar 17, 2004·Current Opinion in Pharmacology·H Y Meltzer
Jan 10, 2008·JAMA : the Journal of the American Medical Association·Ren-Rong WuLehua Li
Mar 15, 2008·Human Psychopharmacology·Martin Baggaley
Apr 9, 2008·Psychoneuroendocrinology·Henderikus KnegteringJim van Os
May 7, 2008·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Alp Uçok, Wolfgang Gaebel

Related Concepts

Antipsychotic Effect
Atypical Antipsychotic [EPC]
Laboratory Procedures
Assay OF Haloperidol
Serotonin Measurement
Antagonist Muscle Action

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.